<DOC>
	<DOCNO>NCT02873689</DOCNO>
	<brief_summary>The purpose study determine efficacy dexlansoprazole compare placebo relief daytime nighttime heartburn 4 week Chinese participant symptomatic non-erosive Gastroesophageal Reflux Disease ( GERD ) .</brief_summary>
	<brief_title>Efficacy Safety Dexlansoprazole Heartburn Relief Chinese Patients</brief_title>
	<detailed_description>The drug test study call dexlansoprazole . Dexlansoprazole test treat heartburn people non-erosive gastroesophageal reflux disease ( GERD ) . This study look heartburn relief people take dexlansoprazole . The study enroll approximately 200 participant . Participants randomly assign one two treatment group 1:1 ratio â€”which remain undisclosed participant study doctor study ( unless urgent medical need ) : - Dexlansoprazole 30 mg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study , ask record time heartburn symptom diary . This multi-center trial conduct China . The overall time participate study 11 week . Participants make 4 visit clinic , contact telephone 5 10 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>1 . Participants identify main symptom burn feel midepigastric area and/or chest area ( , heartburn ) . 2 . Must history symptomatic GERD 6 month longer prior Screening GERD symptom responsive acidsuppressive therapy . 3 . Must episodes heartburn 4 day 7 day prior Day 1 record eDiary . 1 . Has history cancer ( except basal cell carcinoma skin ) , remission least 5 year prior Screening . 2 . Has know history Barrett 's esophagus dysplastic change change suspicious Barrett 's see screen endoscopy . 3 . Participant develop acute upper gastrointestinal bleeding , gastric ulcer ( mucosal defect white coating ) duodenal ulcer ( mucosal defect white coating ) , within 30 day start Screening Visit ( possible inclusion gastric duodenal erosion ) . The participant require chronic use ( great [ &gt; ] 12 dos per month ) nonsteroidal antiinflammatory drug ( NSAIDs ) include cyclooxygenase2 ( COX2 ) NSAIDs within 30 day prior Screening Period throughout study . 4 . Has comorbidities could affect esophagus ( eosinophilic esophagitis , esophageal varix , scleroderma , viral fungal infection , esophageal stricture ) ; history radiotherapy cryotherapy esophagus ; history corrosive physiochemical injury ( possible inclusion study Schatzki 's ring ) . 5 . Has history surgical procedure may affect esophagus ( example , fundoplication mechanical dilatation esophageal stricture ) history gastric duodenal surgery endoscopic removal benign polyp . 6 . Has erosive esophagitis ( EE ) show endoscopy , Screening Period . 7 . Is know acquired immunodeficiency syndrome ( AIDS ) hepatitis , include hepatitis virus carrier : ( , hepatitis B surface antigen HBsantigen ( HBsAg ) positive hepatitis C virus ( HCV ) antibody positive ) . 8 . Has current historical evidence ZollingerEllison syndrome history gastric acid hypersecretion . 9 . Is schedule surgery require hospitalization require surgical treatment his/her participation study . 10 . Has donate lose &gt; 300 milliliter ( mL ) blood volume , undergone plasmapheresis , transfusion blood product within 90 day prior first dose study drug . 11 . Has history alcohol abuse ( define illicit drug use ) , drug addiction 12 month prior Screening . 12 . Participant positive serology result Helicobacter pylorus ( H. pylori ) need eradication therapy study participation period anticipate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>